Check out part 2 of our CMO David Dimmock's interview with CGTLive® about our work using AI to engineer an antisense #oligo for a patient with an ultra-rare disease. brnw.ch/21wM5uS

Tune into part 3 of our CMO David Dimmock's interview with CGTLive® about the Creyon Platform & what's on the horizon at Creyon through 2025. We look forward to advancing more drugs into clinical trials for common disease indications. Watch here: brnw.ch/21wMjoK

Our CEO Chris Hart will join a roundtable discussion at the #RNALeaders Congress on the delivery of small RNA therapeutics. At Creyon Bio, we're reinventing oligonucleotide-based medicines through our innovative approach to drug development. Join us: brnw.ch/21wMjDF

1/2: Congratulations Dr. Nicole Coufal for receiving the Landis Award for Outstanding Mentorship from the NINDS!

2/2: Dr. Coufal was critical in helping Creyon push the first allele selective LNA ASO into the clinic as part of an individualized antisense oligonucleotide therapy in collaboration with the TNPO2 Foundation. brnw.ch/21wMm1h @NINDSDiversity

Exciting news! Creyon has been granted another U.S. patent, which protects our proprietary AI/ML-enabled method for rapid engineering and optimization of therapeutic oligonucleotides. Read our press release to learn more: brnw.ch/21wMolY #AIinHealthcare

Please welcome Serge Messerlian DCVC, to our Board of Directors! With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs. brnw.ch/21wMua9

We're officially welcoming Shaquille Vayda Lux Capital, to Creyon's Board of Directors! Shaq’s diverse experience spanning technology, aerospace and life sciences aligns well with our innovative approach to drug engineering. brnw.ch/21wMuaj

Our CEO Chris Hart latest article in BioInsights explores the future of oligonucleotide-based medicines (OBMs). OBMs are fundamentally programmable drugs and modern AI/ML techniques could help resolve this challenge with purpose-built data. Learn more: brnw.ch/21wMxu6

Our CEO Chris Hart is presenting at #MedInvest2024! Discover how we're engineering OBMs 100x more efficiently and learn about our AI-driven platform that's overcoming delivery challenges with targeted aptamers, transforming treatments for diseases. brnw.ch/21wMP2W

Our CEO Chris Hart is at #MedInvest2024! Learn about how our #AI platform decodes rules for safer, quicker OBM development, overcomes delivery challenges with targeted aptamers, and has recently translated into positive#clinical outcomes. brnw.ch/21wMSoP

Creyon's COO & General Counsel Jason Ferrone will be at the San Diego Biotech Forum on Sept. 25 discussing how our platform is engineering drugs for safety first with the goal of efficiently creating "best-in-class" oligo medicines that will minimize side effects.

Our COO & General Counsel Jason Ferrone will be at the San Diego Biotech Forum on Sept 25, discussing AI in pharma. He'll share how our platform decodes rules for safer, quicker OBM development and how we moved from concept to clinic in just one year. brnw.ch/21wNafF

Join our CEO, Chris Hart, at Oxford Global Biologics US 2024 in San Diego! He'll share insights on our AI-enabled platform for engineering oligonucleotide-based medicines, showcasing how we're transforming discovery to engineering. oxfordglobal.com/discovery-deve…

Join us at the Oligonucleotide Therapeutics Society Meeting! Sankha Pattanayak, Ph.D., will present on how sequence and chemistry collude to drive antisense oligo toxicity. Learn how Creyon is advancing the field of OBMs through innovative research & AI-driven engineering. 2024oligomeeting.com

#ICYMI - Last month, we were granted our 2nd U.S. patent, which protects our proprietary AI/ML-enabled method for rapid engineering and optimization of therapeutic oligonucleotides. Learn more in BioPharma Reporter's article: biopharma-reporter.com/Article/2024/0… #AIinHealthcare

In September, we received our second U.S. patent for AI-powered RNA therapeutic development! Our approach achieves 80-90% success in creating safe compounds and makes development 100x more efficient. Transforming medicine through innovation. creyonbio.com

Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/ #BiotechNews #AIinHealthcare

FDA is moving to reduce animal testing. For a while now, we’ve been in the fast lane to that goal. Our AI-powered platform enables smarter nucleic acid drug design with limited animal studies. The future of drug development is faster & more compassionate. bit.ly/4k2k9Cb

Creyon Bio announces a global licensing and R&D collaboration with Eli Lilly and Company to develop RNA-targeted oligo therapies. With our AI-Powered Oligo Engineering Engine, we’re accelerating novel drug design like never before. creyonbio.com/latest-news/ #BiotechNews #AIinHealthcare